+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adempas"

Disease Analysis: Pulmonary Hypertension - Product Thumbnail Image

Disease Analysis: Pulmonary Hypertension

  • Drug Pipelines
  • April 2021
  • 78 Pages
  • Global
Adempas - Product Thumbnail Image

Adempas

  • Report
  • October 2018
  • 20 Pages
  • Global
From
Adempas - API Insight, 2022 - Product Thumbnail Image

Adempas - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Adempas- Drug Insight, 2019 - Product Thumbnail Image

Adempas- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Adempas (riociguat) is a medication used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a type of cardiovascular drug, which works by relaxing the blood vessels in the lungs to improve blood flow and reduce the workload on the heart. Adempas is a vasodilator, meaning it widens the blood vessels, allowing more blood to flow through them. It is also used to treat people with PAH who have not responded to other treatments. Adempas is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2013. It is manufactured by Bayer AG and marketed by Merck & Co. in the United States. Other companies involved in the Adempas market include Actelion Pharmaceuticals, Gilead Sciences, and United Therapeutics. Show Less Read more